Artrya's AI Cardiac Platform Rally Meets a Revenue Conversion Test

FDA approval and a validating US hospital customer drove a dramatic rally, before a workflow automation delay in converting customers to revenue tested conviction.

31 Jul 2026 · 3 min read

Artrya has rallied from around 70 cents to nearly $5 as its AI-powered cardiac diagnostic platform won FDA approval and its first US hospital customers, with one fund manager setting an internal $50 price target and calling it a potential ten-bagger, before a July revenue conversion delay sent the stock down 34 percent in a single month.

An AI platform tackling the world's biggest killer

Wilson Asset Management described Artrya, founded in Perth in 2019, as a disruptive medical technology company focused on detecting and managing coronary artery disease, the leading cause of death in developed countries, using AI to deliver accurate, non-invasive diagnoses in emergency and primary care settings where diagnostic methods had remained largely unchanged for nearly 50 years. Pengana Capital Group said the stock rose 45 percent following completion of an $80 million capital raise, submission of its final software module to the FDA, and the addition of a new customer to its Sapphire registry program, with the final module, representing around a third of future revenue, expected to gain approval in January.

Real-world validation from a Georgia hospital system

SG Hiscock and Company said it met with Tanner Health, one of Artrya's first commercial customers in the US, a five-hospital system serving West Georgia and East Alabama with around 200,000 emergency department visits a year, describing the discussion as encouraging real-world validation of both the clinical utility and economic proposition of Artrya's Salix platform. Wilson Asset Management said the share price rose following a third-quarter FY2026 result highlighting Artrya's entry into a revenue-generating phase with Tanner Health as its foundation customer. Pengana Capital Group said the stock rose a further 21 percent after broker Bell Potter initiated coverage with a buy rating, and a further 20 percent in the first two weeks of May as Barrenjoey also initiated coverage and Tanner Health conducted an investor roadshow in Australia.

A cross-validation from a peer's big investment

Regal Funds Management's Aldridge called Artrya the standout surprise in his portfolio, having backed the company at 70 cents and watched shares surge toward $5, setting an internal price target of $50 and describing it as a potential ten-bagger. Wilson Asset Management said Artrya is building a diagnostic platform looking at coronary plaque and, soon, blood flow within the heart, having done a good job securing initial FDA approvals for plaque analysis, with approval for the flow module considered imminent, and believes Artrya is materially outperforming US rival HeartFlow. Paradice Investment Management called Artrya an exceptional contributor since initiation, trimming into strength while retaining meaningful exposure to its unique coronary diagnostics platform. Pengana Capital Group said the stock rose 23 percent after fellow Australian-listed AI cardiac imaging company EchoIQ rose 42 percent on a $10 million investment from Pro Medicus, noting Artrya had itself hired Pro Medicus's former chief financial officer the month before.

Aldridge backed the company at 70 cents and has watched its shares surge towards $5 as its AI platform transforms cardiac care. He has slapped an internal price target of $50 on the stock, eyeing it as a potential 10-bagger.

— Regal Funds Management, Article, June 2026

A revenue conversion delay tests conviction

Wilson Asset Management said the share price declined in July, reflecting what it viewed as a knee-jerk reaction to the pace of revenue conversion from customer deployments, an issue management subsequently clarified, with sentiment toward AI-related growth companies proving volatile more broadly. Pengana Capital Group said the stock fell 34 percent having risen 23 percent the previous month, after reporting what had been expected to be its first quarter of material revenue but fell short because of the time required to automate cardiologists' workflows for processing scans, since plaque analysis currently requires additional manual steps before it can be performed.

What fund managers say they are watching next is resolution of the cardiologist workflow automation bottleneck slowing revenue conversion, FDA approval of the flow module, continued commercial contract signings following the Tanner Health validation, and whether the stock's dramatic rally from 70 cents toward $5 marks the start of the ten-bagger trajectory Regal projects or gets tempered by further execution delays.